SAB Biotherapeutics (SAB) as part of Operation Warp Speed, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, and the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) have awarded SAB $57.5 million in expanded scope for its DiversitAb Rapid Response Antibody Program contract for the manufacturing of SAB-185, the company’s clinical stage therapeutic candidate for COVID-19.
“We are pleased to be awarded this additional contract scope, which we believe is a reflection of the compelling science that supports SAB-185’s potential in COVID-19, as well as the urgent need for treatment options amidst the global pandemic. Previous data has indicated that this human polyclonal antibody therapeutic has potent neutralizing activity against SARS-CoV-2, potentially driving more available doses, giving us the confidence to continue to progress our clinical development programs for SAB-185,” said Eddie J. Sullivan, PhD, co-founder, president and CEO of SAB Biotherapeutics. “This manufacturing agreement with BARDA and the Department of Defense supports our vision of bringing a novel, first-of-its-kind human polyclonal antibody therapeutic candidate for COVID-19 to patients, and I am proud of the work by our team and appreciate the continued support from BARDA and JPEO as we continue to rapidly advance SAB-185.”
SAB-185 is currently being tested as a COVID-19 therapeutic in an ongoing Phase 1 trial in healthy volunteers and an ongoing Phase Ib trial in patients with mild or moderate COVID-19. SAB has leveraged its expertise to develop scalable manufacturing capabilities to support clinical activities, and continues to increase capacities in working with contract manufacturing organizations.
Source: Company Press Release